Literature DB >> 6117943

[Nausea and vomiting during chemotherapy of malignant tumors].

R Joss, R Galeazzi, A Gervasi, F Godat, A Goldhirsch, K W Brunner.   

Abstract

Nausea and vomiting are frequent and unpleasant side effects of cancer chemotherapy. Current concepts of pathophysiology and clinical aspects of nausea and vomiting are reviewed. Individual and therapeutic factors are discussed which greatly modify the degree of vomiting. The commercially available antiemetics are tabulated and the individual classes of antiemetics are described. Finally, consideration is given to new approaches to the treatment of nausea and vomiting, including the search for new compounds and better use of currently available agents.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6117943

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  2 in total

1.  Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy.

Authors:  R A Joss; R L Galeazzi; A Bischoff; D D Do; A Goldhirsch; K W Brunner
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

2.  Continuous infusion of high-dose metoclopramide for the prevention of nausea and vomiting in patients receiving cancer chemotherapy.

Authors:  R A Joss; R L Galeazzi; K W Brunner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.